openPR Logo
Press release

BOC Sciences Provides PseudoUridines for Vaccine R&D

01-21-2022 09:37 AM CET | Health & Medicine

Press release from: BOC Sciences

BOC Sciences, a vaccine raw material supplier headquartered in New York, announces providing pseudoUridine products for RNA modification to further promote the research and development of vaccines. According to BOC Sciences' latest report, its annual production of pseudoUridine (key raw material of vaccines) has ranked first in the world.

Massive studies have shown that chemical modification of RNA would affect gene expression in RNA with DNA coding, assuming the actual gene sequence remains unchanged. Insertion, deletion, and base substitution of nucleotides in RNA molecules are examples of RNA modification. Many natural RNAs undergo post-transcriptional alterations, bringing dramatic changes to RNA structure, function, and metabolism. BOC Sciences offers a wide selection of products especially the well-known pseudoUridines so as to facilitate RNA modification. Thus far, it has developed multitudinous pseudoUridine products and their derivatives including phosphate pseudoUridine, phosphoramidite pseudoUridine, and isotope-labeled pseudoUridine.

The human body's immune response to mRNA vaccines is mainly related to uridine (partially composed of uracil). Therefore, BOC Sciences has been contributing to producing various pseudoUridines in place of uridines to synthesize mRNA, which could limit the activation of the host cell's innate immune system by exogenous nucleic acid and the immune system's ability to recognize mRNA. Pseudouracil modification is extensively used in the production of mRNA drugs or vaccines. The well-known manufacturers of mRNA vaccines, Moderna and BioNTech, both employ pseudoUridine from BOC Sciences to maintain the stability of their mRNA products.

Given the broad demand for pseudoUridine products, particularly when mankind is plagued by COVID-19, BOC Sciences has invested large amounts of resources in expanding its production capacity and upgrading the technology. Thus far, its yearly output of pseudoUridines has been reported over 500 kg, signaling the sufficient raw material supply for mRNA vaccine production.

Nowadays, the universal application of pseudoUridines in mRNA modification is still confronted with challenges owing to the difficulties in exploring modification sites. Although some breakthroughs like the ψ-seq technology have been made, BOC Sciences and other researchers are striving for more advanced detection technologies.

Please visit https://nucleotech.bocsci.com for more details about BOC Sciences' pseudoUridine products.

Ramsey Road, Shirley, NY 11967, USA
Alex Brown
account@bocsci.com

BOC Sciences has been involved in the fields of drug development and life sciences for more than ten years, offering researchers a diverse array of chemical substances, such as inhibitors, metabolites, impurities, and natural compounds. Its research team has been working hard to develop strategies and solutions to assist in the pressing issues of drug development. Thanks to its tireless efforts, BOC Sciences is presently the largest provider of pseudoUridine in the world.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BOC Sciences Provides PseudoUridines for Vaccine R&D here

News-ID: 2534187 • Views:

More Releases from BOC Sciences

BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the advantages of small molecular weight, high tumor penetration, low immunogenicity, large-scale synthesis using solid phase synthesis, low
BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Part …
In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands. Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to assess and control impurities in drug substances and drug products. BOC Sciences is confident to employ
High-Standard Fermented Raw Materials that Satisfy the Quality Attributes of Hea …
New York, United States-Oct 12, 2022-Managing raw materials as part of the quality system will ensure that all finished healthcare products can meet quality attributes. As a comprehensive supplier of CRO/CMO/CDMO fermentation services, BOC Sciences is able to provide clients with high-standard raw materials to ensure quality attributes of final healthcare products. Some key factors that should be taken into consideration when selecting raw materials for healthcare products include sufficient
Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022
BOC Sciences successfully participated in TIDES USA 2022 from May 9th to 12th, at Hynes Convention Center, Boston. During the four-day exhibition, experts from BOC Sciences and global visitors are engaged in heated discussions concerning novel advances in peptide and amino acid synthesis, discovery, design, and engineering. BOC Sciences has been preparing for the world's largest gathering of pharmaceutical industry for several months. This year, it attracts a great number

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and